Re: Thoughts on ZCC
in response to
by
posted on
Sep 04, 2021 11:02AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
KayakerBC,
Zenith is ahead clinically to Constellation Pharma and has more potential for drug registration IMO yet Zenith seems to have an enterprise valuation of $300 Million USD to Constelaltion buyout of $1.8 Billion USD. There is a disconnect in valuation for both companies in the same epigenetics space. DM has failed to establish any valuation due to his lack of proper BP management experience... this is sounding like a broken record falling on deaf ears. I guess kudos for those buying ZHCLF for .25 USD and even those PP at $1.5 USD per share if Zenith gets sold for over $1.8 Billion at some point.